Clinical trial • Not applicable • Endocrinology
Para-chloro-2-[18F]fluoroethyl-etomidate for Primary aldosteronism
Not applicable trial of Para-chloro-2-[18F]fluoroethyl-etomidate for Primary aldosteronism. 12 participants.
Overview
- Trial Therapeutic Area
- Endocrinology
- Trial Disease
- Primary aldosteronism
- Trial Stage
- Not applicable
- Drug Modality
- Radiopharmaceutical
Key dates
- Initial CTIS Submission Date
- 14-02-2024
- First CTIS Authorization Date
- 05-06-2024
Trial design
Not applicable trial across 1 site in Netherlands.
- Target Sample Size
- 12
Eligibility
Recruits 12 No vulnerable population selected.
- Vulnerable Population
- No vulnerable population selected
Recruitment
- Planned Sample Size
- 12
- Recruitment Window Months
- 25
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 12
Netherlands
- Earliest CTIS Part Ii Submission Date
- 06-05-2024
- Latest Decision Or Authorization Date
- 05-06-2024
- Processing Time Days
- 30
- Number Of Sites
- 1
- Number Of Participants
- 12
Sites
- Site Name
- University Medical Center Groningen
- Department Name
- Internal Medicine - Endocrinology
- Principal Investigator Name
- Michiel Kerstens
- Principal Investigator Email
- m.n.kerstens@umcg.nl
- Contact Person Name
- Michiel Kerstens
- Contact Person Email
- m.n.kerstens@umcg.nl
- Number Of Participants
- 12
Sponsor
Primary sponsor
- Full Name
- Universitair Medisch Centrum Groningen
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Netherlands
Investigational products
- Investigational Product Name
- Para-chloro-2-[18F]fluoroethyl-etomidate ([18F]CETO)
- Active Substance
- Para-chloro-2-[18F]fluoroethyl-etomidate
- Modality
- Radiopharmaceutical
Related trials
Other published trials that may interest you.